X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs TEVA PHARMA (Israel) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
TEVA PHARMA
Dec-13
DISHMAN PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs3743,026-   
Low Rs1292,629-   
Sales per share (Unadj.) Rs197.81,736.8-  
Earnings per share (Unadj.) Rs21.2108.5-  
Cash flow per share (Unadj.) Rs34.7248.9-  
Dividends per share (Unadj.) Rs2.0094.98-  
Dividend yield (eoy) %0.83.4 23.7%  
Book value per share (Unadj.) Rs179.91,929.2-  
Shares outstanding (eoy) m80.69848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.6 78.1%   
Avg P/E ratio x11.926.1 45.5%  
P/CF ratio (eoy) x7.211.4 63.8%  
Price / Book Value ratio x1.41.5 95.4%  
Dividend payout %9.487.5 10.8%   
Avg Mkt Cap Rs m20,3062,397,720 0.8%   
No. of employees `0000.844.9 1.8%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.732,768.2 58.8%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.12,047.0 100.8%   
INCOME DATA
Net Sales Rs m15,9611,472,765 1.1%  
Other income Rs m2650-   
Total revenues Rs m16,2261,472,765 1.1%   
Gross profit Rs m4,103403,318 1.0%  
Depreciation Rs m1,091119,045 0.9%   
Interest Rs m94428,928 3.3%   
Profit before tax Rs m2,334255,345 0.9%   
Minority Interest Rs m01,160 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-167,620 0.0%   
Tax Rs m624-3,118 -20.0%   
Profit after tax Rs m1,71192,003 1.9%  
Gross profit margin %25.727.4 93.9%  
Effective tax rate %26.7-1.2 -2,188.8%   
Net profit margin %10.76.2 171.6%  
BALANCE SHEET DATA
Current assets Rs m11,018994,700 1.1%   
Current liabilities Rs m9,517867,463 1.1%   
Net working cap to sales %9.48.6 108.8%  
Current ratio x1.21.1 101.0%  
Inventory Days Days11091 121.7%  
Debtors Days Days3596 36.3%  
Net fixed assets Rs m16,304481,038 3.4%   
Share capital Rs m1613,625 4.5%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5161,635,963 0.9%   
Long term debt Rs m4,189753,058 0.6%   
Total assets Rs m29,8053,365,740 0.9%  
Interest coverage x3.59.8 35.3%   
Debt to equity ratio x0.30.5 62.7%  
Sales to assets ratio x0.50.4 122.4%   
Return on assets %8.93.6 248.0%  
Return on equity %11.85.6 209.6%  
Return on capital %17.54.9 355.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786234,683 1.2%  
From Investments Rs m-1,529-83,158 1.8%  
From Financial Activity Rs m-941-281,518 0.3%  
Net Cashflow Rs m316-129,993 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 72.5 Rs / USD

Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare DISHMAN PHARMA With: VENUS REMEDIES  PLETHICO PHARMA  LUPIN LTD  SUN PHARMA  DR. DATSONS LABS  



Today's Market

Sensex Opens Flat; Capital Goods & Banking Stocks Lag(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.5% while the Hang Seng is down 1.2%.

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

Laurus Labs Ltd (IPO)

Dec 6, 2016

Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - CIPLA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS